Company intelligence / Profile preview

EpicentRx

La Jolla, California, United Statesepicentrx.com ↗

Ownership: Private
Employees: ~18
Development stage: Phase 3

Overview

EpicentRx has demonstrated positive clinical results with its lead programs. RRx‑001 has shown improved overall survival and progression-free survival in glioblastoma patients and positive results as a third-line treatment in SCLC. The company’s therapies are designed to be minimally toxic with no dose-limiting toxicities observed to date. AdAPT‑001 is well tolerated in early trials.[3]

Therapeutic areas: OtherGastroenterologyOncologyNeurology
Modalities: Small molecules (e.g., RRx-001)Oncolytic viruses (e.g., AdAPT platform)[1][3][4]
Industry: Biotech

Drug pipeline

6 assets

Nibrozetone

5 more assets in the full pipeline.

Request access →

Partnerships

SciClone Pharmaceuticals International Ltd. – licensing agreement for development/commercialization of RRx‑001 in Greater China.[6]

Beyond the preview

Go deeper on EpicentRx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpicentRx.

Explore the full profile